At this time over 1,000 gene therapy clinical trials are underway, and the global market cap is currently 2.6 billion dollars. It is expected to grow at a CAGR of 20.4% from 2021 to 2028.

While this forecast is encouraging, we believe it is very conservative. Gene therapy is finding, and will continue to find, new applications. Moreover, its uses are not confined to medicine. Complex problems, like the aging process, are modulated by a variety of factors. A larger vector is a necessity. From cosmetic enhancement to interstellar travel, gene therapy’s uses are virtually unlimited when delivered with a vector like BioViva’s CMV. 

The best gene therapy is the one that works safely, predictably, and affordably. This hinges upon its delivery method, its vector. From the beginning BioViva has aimed to tackle the diseases of aging by targeting the aging process with gene therapy. To do this effectively we need to carry a lot of cargo. This is why we’ve developed our own vector. It does what others can’t.  

One time-honored path to success is to offer a universally needed service. During the Gold Rush many more fortunes were made selling picks, pans, and rations to miners than were made by prospecting. Very few miners struck gold, but they all needed tools. BioViva’s CMV is the indispensable technology for the next generation of genetic therapeutics. 

Vectors are currently limited by how much they can carry. Low capacities are typically acceptable when we’re dealing with monogenic issues (caused by a single gene), but the most common problems, diseases we want to treat or qualities we want to enhance, are profoundly polygenic. Because of this unavoidable reality, tackling a problem like heart disease with a standard vector is like trying to make a hatchback do the job of an eighteen-wheeler.

By working right now to design and perfect the vehicle future companies will need, BioViva is positioning itself to remain an industry leader for decades to come. Every clinic, startup, and university needs a quality vector that can carry large quantities of genetic material. Even someone with a cursory familiarity with the field can see that they will soon need a vehicle that can handle their demands. For this reason CMV is poised to become the industry standard.